Диссертация (1174281), страница 23
Текст из файла (страница 23)
Results from IPER registry/F. Casazza, A. Bongarzoni, C.Forgione [et al.]//Thromb. Res. - 2014. pii: S0049-3848(14)00511-8.108. Dahhan, T. Echocardiography in the risk assessment of acute pulmonaryembolism/Dahhan. T, Alenezi. F, Samad. Z [et al.]//Semin. Respir. Crit. Care Med. –2017. – Vol. 38(1). – P. 18-28.109.
Rudski, L.G. Guidelines for the echocardiographic assessment of the right heart inadults: a report from the American Society of Echocardiography endorsed by theEuropean Association of Echocardiography, a registered branch of the European Societyof Cardiology, and the Canadian Society of Echocardiography/L.G.
Rudski, W.W. Lai, J.Afilalo [et al.] // J. Am. Soc. Echocardiogr. – 2010. – Vol. 23(7) – P. 685-713.157110. Jimenez, D. Prognostic significance of deep vein thrombosis in patients presentingwith acute symptomatic pulmonary embolism/ D. Jimenez, D. Aujesky, G. Dıaz [etal.]//Am. J. Respir. Crit. Care Med. – 2010. – Vol. 181(9) – P. 983-991.111.
Yamaki, T. Presence of lower limb deep vein thrombosis and prognosis in patientswith symptomatic pulmonary embolism: preliminary report/Yamaki T, Nozaki M,Sakurai H [et al.]//Eur J Vasc Endovasc Surg. - 2009. – Vol. 37 – P. 225–231.112. Wicki, J. Predicting adverse outcome in patients with acute pulmonary embolism:a risk score/Wicki J, Perrier A, Perneger TV, [et al.]//Thromb Haemost. – 2000. – Vol.84 – P. 548 –552.113.
Meinel, FG. Predictive value of computed tomography in acute pulmonaryembolism: systematic review and meta-analysis/Meinel FG, Nance JW, Schoepf UJ, [etal.]//Am J Med. – 2015. - 128:747–759114. Allgöwer, M. Shock index/Allgöwer M, Burri C. //Dtsch Med Wochenschr.- 1967.– Vol. 92(43) – P. 1947-1950.115. Ates, H. A novel clinical index for the assessment of RVD in acute pulmonaryembolism: Blood pressure index.
/ H. Ates, I. Ates, H. Kundi [et al.] // Am. J. Emerg.Med. – 2017. – Epub pii: S0735-6757(17)30283-8.116. Ates, H. Choice of marker for assessment of RV dysfunction in acute pulmonaryembolism: NT-proBNP, pulmonary artery systolic pressure, mean arterial pressure, orblood pressure index/Ates H, Ates I, Kundi H, [et al.] //Herz. – 2016. - PMID: 27966013117.
Elias, А. Prognostic models in acute pulmonary embolism: a systematic review andmeta-analysis/A. Elias, S. Mallett, M. Daoud-Elias [et al.]//BMJ Open. – 2016. – Vol.6(4). - e010324.118. Sam, A. The shock index and the simplified PESI for identification of low-riskpatients with acute pulmonary embolism/Sam A, Sa´nchez D, Go´mez V, [et al.]//EurRespir J.- 2011. – Vol.
37(4) – P. 762–766.158119. Otero, R. Haemodynamically unstable pulmonary embolism in the RIETE registry.Systolic blood pressure or shock index?/Otero R, Trujillo-Santos J, Cayuela A[et al.]//EurRespir J. – 2007. – Vol. 30 – P. 1111–1116.120. Ozsu, S. Classification of high-risk with cardiac troponin and shock index innormotensive patients with pulmonary embolism/Ozsu S, Erbay M, Durmuş ZG, [etal.]//J Thromb Thrombolysis. – 2017. – Vol. 43(2) – P.
179-183.121. Toosi, M.S. Prognostic value of the shock index along with transthoracicechocardiography in risk stratification of patients with acute pulmonary embolism/ToosiMS, Merlino JD, Leeper KV//Am J Cardiol. - 2008 . – Vol. 101(5) – P. 700-705.122. Righini, M. The Simplified Pulmonary Embolism Severity Index (PESI):validation of a clinical prognostic model for pulmonary embolism/Righini M, Roy PM,Meyer G, [et al.]//J Thromb Haemost.
– 2011. – Vol. 9(10) – P. 2115-2117.123. Zhou, X.Y. The prognostic value of pulmonary embolism severity index in acutepulmonary embolism: a meta-analysis/X.Y. Zhou, S.Q. Ben, H.L. Chen [et al.] // Respir.Res. – 2012. – Vol. 13 – P. 111.124. McGinn, T.G. Users’ guides to the medical literature: XXII: how to use articlesabout clinical decision rules. Evidence-Based Medicine Working Group/ McGinn TG,Guyatt GH, Wyer PC [et al.]//JAMA. - 2000. – Vol. 284 – P. 79–84.125. Aujesky, D. Outpatient versus inpatient treatment for patients with acutepulmonary embolism: an international, open-label, randomised, non-inferiority trial. / D.Aujesky, P.M. Roy, F.
Verschuren [et al.] // Lancet – 2011. – Vol. 378. – P. 41–48.126. Zondag, W. Hestia criteria can safely select patients with pulmonary embolism foroutpatient treatment irrespective of right ventricular function/W. Zondag, L.M.A.Vingerhoets, M.F.
Durian [et al.] // J Thromb. Haemost. – 2013. – Vol. 11 – P. 686–692.127. Davies, C.W.H. Early discharge of patients with pulmonary embolism: a two-phaseobservational study/C.W.H. Davies, J. Wimperis, E.S. Green [et al.] // Eur. Respir. J. –2007. – Vol. 30. – P. 708–714.159128. Beer, J.H. Outpatient treatment of pulmonary embolism is feasible and safe in asubstantial proportion of patients.
/ J.H. Beer, M. Burger, S. Gretener [et al.]//J. Thromb.Haemost. – 2003. – Vol. 1 – P. 186–187.129. Vinson, D.R. Risk stratifying emergency department patients with acute pulmonaryembolism: Does the simplified Pulmonary Embolism Severity Index perform as well asthe original? /Vinson DR, Ballard DW, Mark DG, [et al.] //Thromb Res.- 2016.- Vol. 148– P. 1-8.130. Choi, K.J. Prognostic implications of computed tomographic right ventriculardilation in patients with acute pulmonary embolism/K.J.
Choi, S.I. Cha, K.M. Shin [etal.]//Thromb. Res. – 2014. – Vol. 133 – P. 182–186.131. Dellas, C. A novel H-FABP assay and a fast prognostic score for risk assessmentof normotensive pulmonary embolism/Dellas C, Tschepe M, Seeber V, [et al.]//ThrombHaemost. - 2014. – Vol. 111(5) – P. 996-1003.132. Goldhaber, S.Z. Acute pulmonary embolism: clinical outcomes in the InternationalCooperative Pulmonary Embolism Registry (ICOPER)/Goldhaber SZ, Visani L, De RosaM.//Lancet. – 1999. – Vol.
353 – P. 1386 –1389.133. Kohn, C.G. Prognostic accuracy of clinical prediction rules for early postpulmonary embolism all-cause mortality: a bivariate meta-analysis/C.G. Kohn, E.S.Mearns, M.W. Parker [et al.] // Chest - 2015;. – Vol. 147.– P. 1043–1062.134. Jimenez, D.
Combinations of prognostic tools for identification of high-risknormotensive patients with acute symptomatic pulmonary embolism/D. Jimenez, D.Aujesky, L. Moores [et al.]//Thorax – 2011. – Vol. 66(1) - P. 75–78.135. Squizzato, A. Prognostic clinical prediction rules to identify a low-risk pulmonaryembolism: a systematic review and meta-analysis/ A. Squizzato, M.P. Donadini, L. Galli[et al.]//J Thromb. Haemost.
– 2012. – Vol. 10 – P. 1276–1290.136. Kearon, C. Antithrombotic Therapy for VTE Disease: CHEST Guideline[Электронный ресурс]/ Kearon C, Akl EA, Ornelas J, [et al.] // CHEST. - 2016. Режим доступа: doi: 10.1016/j.chest.2015.11.026160137. Cossette, B. Evaluation of bleeding risk in patients exposed to therapeuticunfractionated or low-molecular-weight heparin: a cohort study in the context of a qualityimprovement initiative/Cossette B, Pelletier ME, Carrier N, [et al.]//Ann Pharmacother.
2010. – Vol. 44(6) – P. 994–1002.138. van Dongen CJ, van den Belt AG, Prins MH, [et al.] Fixed dose subcutaneous lowmolecular weight heparins vs. adjusted dose unfractionated heparin for venousthromboembolism. van Dongen CJ, van den Belt AG, Prins MH, [et al.] CochraneDatabase Syst Rev 2004;(4):CD001100.139.
Stein, P.D. Incidence of thrombocytopenia in hospitalized patients with venousthromboembolism/Stein PD, Hull RD, Matta F, [et al.]//Am J Med. - 2009. – Vol.122(10) – P. 919–930.140. Prandoni, P. The incidence of heparin-induced thrombocytopenia in medicalpatients treated with low-molecular-weight heparin: a prospective cohort study/PrandoniP, Siragusa S, Girolami B, [et al.]//Blood. - 2005. – Vol. 106(9) – P.
3049–3054.141. Kearon, C. Antithrombotic therapy for VTE disease: Antithrombotic Therapy andPrevention of Thrombosis, 9th ed: American College of Chest PhysiciansEvidence-BasedClinical Practice Guidelines/Kearon C, Akl EA, Comerota AJ, [et al.]//Chest. – 2012. –Vol/ 141(2 Suppl) – eP. 419S-494S.142. Carrier, M. Efficacy and safety of anticoagulant therapy for the treatment of acutecancer-associated thrombosis: a systematic review and meta-analysis/Carrier M,Cameron C, Delluc A, [et al.]//Thromb Res. – 2014. – Vol. 134(6) – P. 1214-1219.143. Bochenek, T. The treatment of venous thromboembolism with low-molecularweight heparins. A metaanalysis/Bochenek T, Nizankowski R.//Thromb Haemost. –2012. – Vol.
107(4) - 699-716.144. Samama, M.M. Contemporary laboratory monitoring of low molecular weightheparins/Samama MM, Poller L.//Clin Lab Med. – 1995. – Vol. 15(1) – P. 119–123.161145. Warkentin, T.E. Heparin-induced thrombocytopenia associated with fondaparinux/Warkentin TE, Maurer BT, Aster RH//N Engl J Med. – 2007.
– Vol. 356(25) – P. 2653–2655.146. Bu¨ller, H.R. Subcutaneous fondaparinux versus intravenous unfractionatedheparin in the initial treatment of pulmonary embolism/Bu¨ller HR, Davidson BL,Decousus H, [et al.]//N Engl J Med. - 2003. – Vol. 349(18) - P.
1695–1702.147. Castellucci, L.A. Clinical and safety outcomes associated with treatment of acutevenous thromboembolism: a systematic review and meta-analysis/Castellucci LA,Cameron C, Le Gal G [et al.]//JAMA. – 2014. – Vol. 312(11) – P. 1122-1135.148. van Es, N. Direct oral anticoagulants compared with vitamin K antagonists foracute venous thromboembolism: evidence from phase 3 trials/van Es N, Coppens M,Schulman S, [et al.]//Blood. – 2014.
– Vol. 124(12) – P. 1968-1975.149. Chai-Adisaksopha, C. The impact of bleeding complications in patients receivingtarget-specific oral anticoagulants: a systematic review and meta-analysis/ChaiAdisaksopha C, Crowther M, Isayama T, [et al.]//Blood. – 2014. – Vol. 124(15) – P.2450-2458.150. Bloom, B.J.
Meta-analysis of randomized controlled trials on the risk of bleedingwith dabigatran/Bloom BJ, Filion KB, Atallah R, [et al.//Am J Cardiol. – 2014. – Vol.113(6) - P. 1066-1074.151. Touma, L. A metaanalysis of randomized controlled trials of the risk of bleedingwith apixaban versus vitamin K antagonists/Touma L, Filion KB, Atallah R, [et al.]//AmJ Cardiol. – 2015. – Vol. 115(4) – P. 533-541.152. Kang, N. Indirect treatment comparison of new oral anticoagulants for thetreatment of acute venous thromboembolism/Kang N, Sobieraj DM//Thromb Res. – 2014.– Vol 133(6) – P.
1145-1151.153. Douketis, J. Patient-level meta-analysis: effect of measurement timing, threshold,and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked162venous thromboembolism/Douketis J, Tosetto A, Marcucci M, [et al.]//Ann Intern Med.2010. – Vol. 153 – P. 523–531.154.
Douketis, J. Risk of recurrence after venous thromboembolism in men and women:patient level metaanalysis/Douketis J, Tosetto A, Marcucci M [et al.]//BMJ. – 2011. –Vol. 342 – P. d813.155. Palareti, G. D-dimer to guide the duration of anticoagulation in patients withvenous thromboembolism: a management study/Palareti G, Cosmi B, Legnani C[etal.]//Blood. – 2014. – Vol. 124(2) – P. 196-203.156. Kearon, C. D-dimer testing to select patients with a first unprovoked venousthromboembolism who can stop anticoagulant therapy: a cohort study/Kearon C, SpencerFA, O’Keeffe D, [et al.]//Ann Intern Med. – 2015. – Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
